Home/Pipeline/FARAPULSE PFA System

FARAPULSE PFA System

Atrial Fibrillation

FDA ApprovedGlobal LaunchNCT04612244

Key Facts

Indication

Atrial Fibrillation

Phase

FDA Approved

Status

Global Launch

Company

Boston Scientific

About Boston Scientific

Boston Scientific is a diversified medical device leader with a mission to advance science for life by delivering innovative, minimally invasive solutions. The company has achieved sustained growth through strategic diversification beyond its cardiovascular roots into high-growth areas like neuromodulation and endoscopy, supported by a robust R&D engine and strategic acquisitions. Its strategy focuses on addressing unmet clinical needs with category-leading technologies, driving global expansion, and improving patient outcomes while delivering shareholder value.

View full company profile

Therapeutic Areas

Cardiovascular Neuromodulation Endoscopy Oncology Urology Pelvic Health

Other Atrial Fibrillation Drugs

Drug	Company	Phase	Status
Non-viral gene therapy for Atrial Fibrillation	Inomagen Therapeutics	Pre-clinical	Active
AP31969	Acesion Pharma	Phase 2	Active
OMT-28	OMEICOS Therapeutics	Phase 2	Active